Advertisement
Advertisement
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
AstraZeneca’s booth at the China International Supply Chain Expo in Beijing, July 17, 2025. Photo: EPA
Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

Biomedicine: Industry Trends

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

A man demonstrates a robotic hand with a brain-computer interface at the China International Import Expo on November 7, 2025. Neuracle’s regulatory milestone underscores China’s accelerating push in neurotechnology. Photo: AFP
China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Advertisement
Advertisement
Advertisement
Two Sessions 2026

China to pursue commercial health insurance to ease strain, support innovation

Commercial health insurance enters China’s policy agenda as an ageing population and costs strain basic coverage.

The move signals efforts to strengthen the country’s social safety net and support the growth of innovative drugs and medical devices. Photo: Getty Images
Insilico

Insilico Medicine advances Middle East push with UAE AI drug discovery deal

Hong Kong-listed biotech firm’s shares jump after announcing partnership to use AI tools in drug discovery in the United Arab Emirates.

Two Sessions 2026

China and Hong Kong should relax biotech listing rules, venture capitalist says

Foreign investors are returning to China’s healthcare sector, but IPO bottlenecks and takeover rules could deter deals, VC Nisa Leung says.

Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images
Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua
Artificial intelligence

Chinese AI drug researcher XtalPi expects to turn first annual profit

Shenzhen-based company projects net profit of at least US$14.5 million in 2025 on narrowing losses in core businesses, investment gains.

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

China’s private sector

Wave of Chinese biotech deals builds with US$1.2 billion Harbour BioMed pact

Deal involving an antibody asset ‘goes beyond a traditional licensing transaction’, founder and CEO says.

Harbour BioMed’s antibody programme focuses on tumour-killing effects. Photo: Handout
Made in China 2025

After boost from viral dance challenge, Chinese medicine firm’s shares languish

Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.

The combined daily production capacity of ibuprofen and paracetamol in China surged fourfold to 202 million tablets by late December 2022. Photo: Shutterstock
China’s private sector

Lab monkey price tag climbs to US$20,000 thanks to China’s biotech boom

The cost of a single monkey exceeds the average annual salary in China and approaches a pandemic-era spike amid growth in drug licensing deals.

Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off

Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny.

WuXi Biologics credits the performance to its “follow and win the molecule” strategy, which aims to secure work across the full lifecycle of client drugs. Photo: Shutterstock
Made in China 2025

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

China’s private sector

Biomedicine | China challenges US in new drugs after industry transformation

Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.

China challenges US in new drugs after industry transformation
Made in China 2025

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

A view of the Shanghai facility of Fosun Pharma’s biopharma unit Henlius. Photo: Handout
IPO

Morgan Stanley sees another record year for Hong Kong IPOs as pipeline hits 450

Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.

Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

Global investors have reaped sizeable rewards from their investments in Hong Kong-listed biotech and pharmaceutical companies in the past year. Photo: Shutterstock
US-China relations

Opinion | China has Trump 2.0 to thank for emerging stronger in tech and trade

As intense US-China competition becomes the new normal, pressure has strengthened China’s capacity to adapt rather than deter it from its long-term ambitions.

videocam
President Xi Jinping attends a high-level reception to ring in the Lunar New Year at the Great Hall of the People in Beijing, on January 27, 2025. Photo: Xinhua
Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement